Erlotinib Induced Trichomegaly of the Eyelashes

Jeon, Sang-Hoon; Ryu, Jeong‐Seon; Choi, Gwang‐Seong; Kim, Jung-Soo; Kwon, Hea Yoon; Kim, Minsu; Nam, Hae-Seong; Cho, Jae Hwa; Kwak, Sang Mi; Lee, Hong Lyeol; Kim, Hyun-Jung; Hong, Geun-Jeong

doi:10.4046/trd.2013.74.1.37

Cited by 8 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the patient of the current study presented an activating mutation (L858R) in exon 21 and experienced a moderate rash on her face, chest and back; however, the patient did not present similar progression-free survival benefits. Considering the present case along with similar cases previously reported in the literature (5,16,25) led to several interesting observations. Patients who manifested trichomegaly also exhibited a poor progression-free survival (3-7 months), and disease progression occurred after 1-3 months of trichomegaly.…”

Section: A B C Dsupporting

confidence: 48%

“…Erlotinib-associated eyelash trichomegaly has been reported only in a small number of case reports (4,5,(15)(16)(17). To the best of our knowledge, erlotinib-induced trichomegaly has not been previously reported in Chinese patients.…”

Section: Discussionmentioning

confidence: 71%

“…Based on these results, the Food and Drug Administration (FDA) approved erlotinib for the treatment of patients with locally advanced or metastatic NSCLC after progression on at least one prior chemotherapy regimen. With the wide use of EGFR tyrosine kinase inhibitors (TKIs) in patients with NSCLC, an increasing number of side effects have been observed, including skin rash, diarrhea, stomatitis and eyelash trichomegaly (4,5). The adverse events most frequently reported by erlotinib-treated patients are rash (56.0%) and diarrhea (62.0%) (6).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review

et al. 2015

View full text Add to dashboard Cite

Abstract. Inhibitors of epidermal growth factor receptor (EGFR), including tyrosine kinase inhibitors (TKIs), present significant clinical benefits in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with an EGFR mutation. However, TKI treatment also results in unwanted cutaneous toxic side effects, such as a skin rash. Eyelash trichomegaly is rarely reported as a side effect; however, it causes cosmetic issues or eyeball irritation in patients, which may result in the early termination of TKI treatment. Therefore, although TKI-induced eyelash trichomegaly is rare, it should be considered carefully by lung cancer physicians. The present study reported a case of erlotinib-induced eyelash trichomegaly in a 65-year-old Chinese female patient suffering from NSCLC with an EGFR mutation. To the best of our knowledge, this is the first reported case of erlotinib-induced trichomegaly in a Chinese patient.

show abstract

Section: A B C Dsupporting

confidence: 48%

Section: Discussionmentioning

confidence: 71%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Eyelash trichomegaly following treatment with erlotinib in a non-small cell lung cancer patient: A case report and literature review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[ 7 8 ] Trichomegaly of eyelashes due to EGFR inhibitors is usually seen after 2–5 months of treatment and can be associated with hypertrichosis in other areas; however, this is not the rule. [ 9 ]…”

Section: Discussionmentioning

confidence: 99%

Eyelashes trichomegaly: An unusual side effect of gefitinib therapy

et al. 2018

View full text Add to dashboard Cite

Evolution of targeted therapy has changed the spectrum of treatment in oncology since the past two decades as lots of newer agents are being added to the pharmacologic armamentarium of cancer therapy. Epidermal growth factor receptor inhibitors form one such advancing field with many newer agents being investigated and they are used in wide variety of malignancies such as head and neck cancer, lung cancer, and even gastrointestinal malignancies such as pancreatic cancer. Various troublesome side effects of these agents include diarrhea, severe fatigability, severe skin rashes, and deranged liver function tests which may require treatment interruption or dose reduction resulting in decreased response to treatment. However, some of the side effects may not require dose modification but incidentally observed and does not impact patient's quality of life. One such effect is trichomegaly which is very rarely observed with such agents. Herein, this conversation we report a 52-year-old female case of metastatic carcinoma lung who developed trichomegaly of eyelashes while on gefitinib therapy.

show abstract

“…3 In a typical course, trichomegaly develops between the second and fifth month of EGFR inhibitor treatment. 4 An Asian study reported that 2% of patients prescribed EGFR inhibitor treatment had trichomegaly. 5 The EGFR inhibitor is also well known to cause a series of cutaneous adverse effects known as the PRIDE syndrome (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness).…”

Section: Pictorial Medicinementioning

confidence: 99%